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Introduction {#sec005}
============

Urothelial carcinoma (UC) is one of the most common urologic cancers. Among urogenital tumors, it is only second to prostate cancer. The majority of UCs is bladder cancer, and the incidence of bladder cancer ranked 11^th^ in global cancer statistics and seventh in malignancy for male tumors \[[@pone.0134940.ref001]\]. In clinical practice, cystoscopy with a biopsy is the gold standard for diagnosis. It's aggressive and relatively inconvenient as a follow-up monitoring approach. Urinary cytology is a noninvasive examination for urothelial carcinoma but has a low and unstable detection rate. The sensitivity and specificity of urinary cytology are 13--75% and 85--100%, respectively. Additionally, urinary cytology is likely to be influenced by external factors \[[@pone.0134940.ref002],[@pone.0134940.ref003]\]. Liquid-based cytology (LBC) is widely used in cervical cancer screening but has been confined to this application since it was approved by the FDA in 1996. Recently, this slide-making technique has been noted in other medical fields, such as breast cancer, sputum cytology of lung cancer, and especially urinary cytology. Some studies indicate that LBC may improve the sensitivity of bladder cancer detection and the background of micrographs \[[@pone.0134940.ref004]--[@pone.0134940.ref007]\]. We evaluated the diagnostic value of the LBC techniques in urothelial carcinoma with evidence-based medicine methods.

Materials and Methods {#sec006}
=====================

Search strategy {#sec007}
---------------

A literature search of PubMed, Embase, Web of Science, Cochrane Library, Chinese BioMedical Literature Database (CBM) and Chinese National Knowledge Infrastructure (CNKI) was conducted by two independent investigators (DLS and YL) to retrieve the clinical researches through to September 2014. The search terms used were "liquid based cytology", "thinprep", "autocyte", "surepath", "cellpreplus", "thin layer", "monolayer", "bladder cancer" and "urothelial carcinoma". References in the retrieved literature and previous systematic reviews were identified for any relevant studies. The eligibility criteria in this study included any cytological diagnostic study including the LBC techniques. Studies with the following criteria were excluded: (1) the research subjects were special patients or had unusual situations, such as confinement to atypical cells or low-to-high grade urothelial carcinoma; (2) related data could not be extracted nor calculated; or (3) duplicate published articles or articles with overlapping patients. This systematic review was performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) \[[@pone.0134940.ref008]\].

Quality assessment and data extraction {#sec008}
--------------------------------------

The quality of the included studies was independently assessed by QUADAS-2 \[[@pone.0134940.ref009]\], which was recommended for a diagnostic accuracy review by Cochrane Systematic Review \[[@pone.0134940.ref010]\]. The data extraction was performed and cross-checked by 2 independent investigators (YL and DLS). If there was a discrepancy in opinions, it was solved by group discussion. The information extracted from these citations included the name of the first author, year of publication, regions, urine sample, et al. The data were extracted from the original outpatient data, if possible. The extracted data included the number of true positives (tp), false positives (fp), false negatives (fn) and true negatives (tn) using LBC and traditional cytospin, if the data were available. The data from patients with previous urothelial carcinoma were not excluded. When a study included no direct data, we calculated the incidence using a basic formula (such as "sensitivity" = tp/(tp+fn), "specificity" = tn/(tn+fp)).

Statistical analysis {#sec009}
--------------------

Stata 13 (Stata Corp LP, College Station, TX, USA) was used to conduct the synthesis analysis and perform the publication bias detection. The effect size included sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, area under the curve (AUC) and post-test probability, and bivariate mixed-effects binary regression model was used \[[@pone.0134940.ref011]\]. When compared sensitivity of different cytology techniques and different tumor grades, Cochrane's Q test and *I* ^*2*^ statistic were performed for heterogeneity. P≥0.1 and *I* ^*2*^ \<50% indicated there was no significant heterogeneity, in which case a fixed model (Mantel-Haenszel method) was applied. Otherwise was significant heterogeneity, a random model (Der Simonian and Laird method) was used. A comparison of LBC and traditional cytospin cytology was also performed, and the risk ratio (RR) was measured. Leave-one-out method was used for the sensitivity analysis. Publication bias for diagnostic accuracy test was detected by Deek's funnel plot asymmetry test \[[@pone.0134940.ref012]\]. A P≤0.10 was considered significant publication bias. A 2-tailed P≤0.05 indicated statistical significance for other than outcomes of publication bias test.

Results {#sec010}
=======

Literature filtration and quality assessment {#sec011}
--------------------------------------------

Six hundred eighty-five citations were searched using the initial search strategy. No meta-analyses had been published. Nineteen citations \[[@pone.0134940.ref013]--[@pone.0134940.ref031]\], which included 15 English references \[[@pone.0134940.ref013],[@pone.0134940.ref015]--[@pone.0134940.ref024],[@pone.0134940.ref026]--[@pone.0134940.ref029]\] and 4 Chinese articles \[[@pone.0134940.ref014],[@pone.0134940.ref025],[@pone.0134940.ref030],[@pone.0134940.ref031]\], were included. No randomized controlled trials were included. The 19 studies included 8293 patients (1933 cancer patients and 6360 control patients). The screening flow chart is shown in [Fig 1](#pone.0134940.g001){ref-type="fig"}, and [Table 1](#pone.0134940.t001){ref-type="table"} shows the basic characteristics of the included studies. The quality assessment of included studies is shown in [Fig 2](#pone.0134940.g002){ref-type="fig"} as a comprehensive result determined by QUADAS-2.

![Flow diagram of studies retrieved.](pone.0134940.g001){#pone.0134940.g001}

![Quality assessment of the included studies.](pone.0134940.g002){#pone.0134940.g002}
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###### Characteristics of included studies.

![](pone.0134940.t001){#pone.0134940.t001g}

  Studies \[reference\]                             Year   Regions         Gold Standard   Cancer type   Cytology diagnostic category   Stain    Urine Samples   tp    fp    fn    tn
  ------------------------------------------------- ------ --------------- --------------- ------------- ------------------------------ -------- --------------- ----- ----- ----- ------
  Lodde \[[@pone.0134940.ref019]\]                  2003   Italy+Austria   His             uc            N\\A\\S\\P                     Pap+HE   vu              22    2     29    38
  Lodde \[[@pone.0134940.ref020]\]                  2004   Italy+Austria   Cys+Bio         bc            N\\A\\S\\P                     Pap+HE   vu              21    5     26    49
  Piaton \[[@pone.0134940.ref022]\]                 2005   France          Cys+His         buc           N\\A\\S\\P                     Pap      vu+cu           42    4     19    133
  Lodde \[[@pone.0134940.ref018]\]                  2006   Italy+Austria   Cys+bio         buc           N\\A\\S\\P                     Pap      vu              49    9     52    167
  Mian \[[@pone.0134940.ref021]\]                   2006   Italy           Cys+His         buc           N\\A\\S\\P                     Pap      vu              116   10    182   1578
  Hwang \[[@pone.0134940.ref015]\]                  2007   Korea           Bio             bc            N\\A\\S\\P                     Pap      NA              18    1     11    43
  Sng \[[@pone.0134940.ref026]\]                    2007   Singapore       Bio             uc            N\\A\\P                        Pap      vu              16    1     4     5
  Zhao \[[@pone.0134940.ref031]\]                   2008   China           His             uc            N\\A\\S\\P                     Pap      vu              188   13    86    83
  Sullivan \[[@pone.0134940.ref028]\]               2009   USA             Cys+Bio         bc            N\\A\\P                        Pap      vu              5     2     19    72
  Ye \[[@pone.0134940.ref030]\]                     2011   China           Cys+Bio         bc            N\\A\\S\\P                     HE       vu              39    1     21    147
  Saeb-Parsy-Aberdeen \[[@pone.0134940.ref024]\]    2012   UK              Cys+Bio         bc            N\\A-S\\P                      Pap      vu              15    11    6     85
  Saeb-Parsy-Cambridge \[[@pone.0134940.ref024]\]   2012   UK              Cys+Bio         bc            N\\A-S\\P                      Pap      vu              10    12    6     38
  Son \[[@pone.0134940.ref027]\]                    2012   Korea           His             bc            N\\A\\S\\P                     Pap      vu              25    0     26    37
  Li \[[@pone.0134940.ref017]\]                     2013   China           His             uc            N\\A\\S\\P                     Pap      vu              76    6     28    55
  Shen \[[@pone.0134940.ref025]\]                   2013   China           Cys+His         buc           NA                             NA       vu              28    0     32    62
  van Hemel \[[@pone.0134940.ref029]\]              2013   Netherlands     His             uc            Benign\\Abnormal               Pap      NA              61    17    57    40
  Dimashkieh \[[@pone.0134940.ref013]\]             2013   USA             Cys+His         bc            N\\A\\S\\P                     NA       vu+wu+cu        15    11    30    734
  Piaton \[[@pone.0134940.ref023]\]                 2014   France          Cys+His         uc            N\\A-US\\A-H\\P                Pap      NA              85    5     21    50
  Li \[[@pone.0134940.ref014]\]                     2014   China           Cys+His         bc            N\\A\\S\\P                     HE       vu              50    1     18    127
  Kim \[[@pone.0134940.ref016]\]                    2014   Korea           TURB+Bio        bc            N\\A\\S\\P                     Pap      wu              231   143   148   2563

Abbreviations: uc-urothelial carcinoma, bc-bladder cancer; vu-void urine, wu-washing urine, cu-catheterized urine; Cys-cystoscopy, His-histology, Bio-biopsy; N-negative, A-atypical, S-suspicious, P-positive, A-US---atypical unknown significance, A-H---atypical cannot exclude high grade; Pap-papanicolaou, HE-hematoxylin eosin; NA-not applicable; tp-true positive, fp-false positive, fn-false negative, tn-true negative.

Diagnostic results {#sec012}
------------------

Before the quantitative analysis, we conducted a threshold effect, the result of which was a Spearman correlation coefficient of 0.361, P = 0.118\>0.10, which could be considered no significant threshold effect. Then, the quantitative analysis yielded the comprehensive results shown in Figs [3](#pone.0134940.g003){ref-type="fig"} and [4](#pone.0134940.g004){ref-type="fig"}, The pooled sensitivity and specificity of LBC were 0.58 (0.51, 0.65) and 0.96 (0.93, 0.98), respectively. The pooled positive and negative likelihood ratios were 13.8 (8.0, 24.0) and 0.44 (0.37, 0.52), respectively. The pooled DOR was 31 (18, 56). The pre-test probability was 0.23, and the positive and negative post-test probability was 80% and 12%, respectively. The AUC of the summary receiver operating characteristic (SROC) was 0.83 (0.80, 0.86), which indicated a moderate diagnostic value. All pooled results were tabulated in [Table 2](#pone.0134940.t002){ref-type="table"}.

![Pooled sensitivity, specificity, positive DLR and negative DLR.](pone.0134940.g003){#pone.0134940.g003}

![Pooled diagnostic odds ratio and SROC of the included studies.](pone.0134940.g004){#pone.0134940.g004}
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###### Pooled diagnostic results of included studies.

![](pone.0134940.t002){#pone.0134940.t002g}

  Effect Size         Sensitivity         Specificity         LR-                 LR+                   DOR
  ------------------- ------------------- ------------------- ------------------- --------------------- ----------------------
  Pooled Results      0.58 (0.51--0.65)   0.96 (0.93--0.98)   0.44 (0.37--0.52)   13.82 (7.97--23.96)   31.42 (17.67--55.86)
  P value of Q test   \<0.01              \<0.01              \<0.01              \<0.01                \<0.01
  I^2^ statistic      87.26%              93.74%              87.98%              87.52%                100%

Abbreviations: LR-: negative likelihood ratio. LR+: positive likelihood ratio. DOR: diagnostic odds ratio.

### LBC versus CS {#sec013}

Only 4 studies \[[@pone.0134940.ref014],[@pone.0134940.ref016],[@pone.0134940.ref026],[@pone.0134940.ref027]\] ([Fig 5](#pone.0134940.g005){ref-type="fig"}) of the 19 citations compared the sensitivity of LBC and traditional cytospin cytology (CS). I^2^ and P value were 0% and 0.590, respectively. Fixed model was used and the synthetic risk ratio (RR) was 1.03 (95%CI 0.94--1.14), P = 0.524, which indicated that LBC did not yield a significant improvement in the sensitivity of detection. Sensitivity analysis did not alter the outcome ([Fig 6](#pone.0134940.g006){ref-type="fig"}).

![Comparison of sensitivity of Liquid Based Cytology versus Traditional Cytospin Cytology.](pone.0134940.g005){#pone.0134940.g005}

![Sensitivity analysis of Comparison of sensitivity of LBC versus CS.](pone.0134940.g006){#pone.0134940.g006}

### Tumor grade category {#sec014}

A sensitivity comparison was performed between the low-grade and high-grade urothelial carcinoma, in which G1 and G2 were set as the low-grade urothelial carcinoma (LGUC) and G3 as the high-grade urothelial carcinoma (HGUC). Both I^2^ of 83.1% and the P value of Cochrane Q test showed significant heterogeneity. Random effect model was used. The forest plot showed that LGUC cytological diagnosis had a significantly lower sensitivity than HGUC, RR = 0.54 (0.43, 0.66), P\<0.001 ([Fig 7](#pone.0134940.g007){ref-type="fig"}). Sensitivity analysis did not change the significance (The result was omitted).

![Sensitivity of LGUC versus HGUC.](pone.0134940.g007){#pone.0134940.g007}

### Publication bias {#sec015}

The result of Deek's plot is shown in [Fig 8](#pone.0134940.g008){ref-type="fig"} which indicates absence of significant publication bias (P = 0.41).

![Publication bias of included studies.\
1/root(ESS) meant inverse root of effective sample sizes. Each circle represented an included study.](pone.0134940.g008){#pone.0134940.g008}

Discussion {#sec016}
==========

Urinary cytology has a long history of widespread use and irreplaceable clinical detection. As a noninvasive exam, urinary cytology had the disadvantage of relatively low and unstable sensitivity, which has led to its limited application. Additionally, a traditional urinary cytology cytospin slide only shows a few cells, which can be confounded with red blood cells, white blood cells and other non-urothelial cells or impurities. This could decrease the identification of urothelial cells. LBC is an innovative slide-making technique that was initially applied in cervical cancer screening, and it greatly reduced the slide-making time, obliterated the non-urothelial cells and mucus in the urine, humidified slides and decreased cell degeneration by a preservation solution, and improved slide quality (including background, cell dispersion, and reducing the confounding cells) \[[@pone.0134940.ref005]--[@pone.0134940.ref007],[@pone.0134940.ref032]\]. Additionally, the automatic processing of LBC is another positive feature \[[@pone.0134940.ref027]\]. Above all, LBC reduces the probability of atypical urothelial cells on the slide, which causes low and unstable cytological sensitivity \[[@pone.0134940.ref006],[@pone.0134940.ref007]\].

Many studies have verified that the sensitivity of urinary cytology differed between the urothelial carcinoma grades: the higher grade, the higher sensitivity \[[@pone.0134940.ref033],[@pone.0134940.ref034]\]. This may result from well-differentiated low-grade urothelial carcinoma causing indistinguishable cell morphology and a tight connection between cancer cells with a minimal probability to fall off. Our pooled study with LBC confirmed these results. Compared with HGUC, LGUC detection had a significantly lower sensitivity, RR = 0.54 (0.43, 0.66) P\<0.001. The different urine acquisition approaches were another impact factor affecting the sensitivity. Wash urine or bladder irrigation was more sensitive than catheterized. Void urine had the lowest sensitivity \[[@pone.0134940.ref035],[@pone.0134940.ref036]\]. Few studies compared the methods using urine category; thus, the urine category subgroup was not analyzed. Additionally, another decisive impact factor was staining, which determined the observational method and results. The HE stain is a traditional staining method for urinary cytology, while for the LBC stain, the majority were stained with papanicolaou (Pap). Because the principal focus of cytology for urothelial carcinoma is the cell nucleus, both HE and Pap stained the cell nucleus. Acridine orange fluorescence improved sensitivity to 77.1% and was associated with tumor grade and stage. Higher sensitivity was observed with acridine orange fluorescence than the Feulgen stain, and the lowest sensitivity was observed with the HE stain \[[@pone.0134940.ref037]\]. However, combining LBC with different staining methods to improve sensitivity of urinary cytology has yet to be verified by further studies.

Currently, research hotspots regarding urothelial carcinoma detection are concentrated on tumor markers, such as NMP22, BTA, and Survivin \[[@pone.0134940.ref038]\]. A noticeable improvement in sensitivity was shown when LBC was used for uCyt+/immunoCyt in bladder cancer test \[[@pone.0134940.ref019],[@pone.0134940.ref021],[@pone.0134940.ref039]\], but this test had low specificity, and was more expensive and time consuming with lower efficiency. The current trend is to combine LBC with other laboratory tests for urothelial carcinoma detection.

The following are the strengths of our meta-analysis: This is a first meta-analysis that evaluates the diagnostic accuracy of liquid based cytology in urothelial carcinoma. Additionally, we compared the sensitivity between liquid based cytology and traditional cytospin cytology and presented no sensitivity improvement was observed. Additionally, the fact that LBC versus CS pooled effect yielded an I-square value of 0% and the sensitivity analysis showed a stable pooled effect. Meanwhile, our meta-analysis has some limitations. First, some studies on LBC diagnostic accuracy of urothelial carcinoma in outpatients were limited in cured patients with urothelial carcinoma, which led to a selection bias of patients. Second, blinding in most of the included studies was not certain. Third, a comparison between LBC and traditional cytospin cytology was conducted in only a few studies. Fourth, the heterogeneity could not be avoided. Most other forest plots were heterogeneous (high I-square values) which are limitations. The cytology diagnostic category, stain methods and urine samples possibly affect the heterogeneity of the included studies. Hence, higher quality diagnostic trials comparing LBC with cytospin cytology are expected to confirm our results.

Conclusion {#sec017}
==========

In summary, our study showed comprehensive diagnostic results for LBC including sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio. Low-grade urothelial carcinoma diagnosis had a significantly lower sensitivity than high-grade urothelial carcinoma. Based on the few included references comparing LBC with traditional cytospin cytology, LBC did not show any improvement in sensitivity. More studies are needed for further validation. However, the automation and excellent slides prepared using the LBC techniques made the slide-making process highly efficient, which could a good reason to promote this technique.
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